JP2019524898A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019524898A5 JP2019524898A5 JP2019531547A JP2019531547A JP2019524898A5 JP 2019524898 A5 JP2019524898 A5 JP 2019524898A5 JP 2019531547 A JP2019531547 A JP 2019531547A JP 2019531547 A JP2019531547 A JP 2019531547A JP 2019524898 A5 JP2019524898 A5 JP 2019524898A5
- Authority
- JP
- Japan
- Prior art keywords
- human patient
- disease
- huntington
- patient
- ability
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021078504A JP2021119186A (ja) | 2016-08-24 | 2021-05-06 | 機能低下を治療するためのプリドピジンの使用 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662379175P | 2016-08-24 | 2016-08-24 | |
| US62/379,175 | 2016-08-24 | ||
| US201662395263P | 2016-09-15 | 2016-09-15 | |
| US62/395,263 | 2016-09-15 | ||
| US201662411511P | 2016-10-21 | 2016-10-21 | |
| US62/411,511 | 2016-10-21 | ||
| US201662416685P | 2016-11-02 | 2016-11-02 | |
| US62/416,685 | 2016-11-02 | ||
| PCT/US2017/048461 WO2018039477A1 (en) | 2016-08-24 | 2017-08-24 | Use of pridopidine for treating functional decline |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021078504A Division JP2021119186A (ja) | 2016-08-24 | 2021-05-06 | 機能低下を治療するためのプリドピジンの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019524898A JP2019524898A (ja) | 2019-09-05 |
| JP2019524898A5 true JP2019524898A5 (https=) | 2019-10-17 |
| JP6912574B2 JP6912574B2 (ja) | 2021-08-04 |
Family
ID=61241181
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531547A Active JP6912574B2 (ja) | 2016-08-24 | 2017-08-24 | 機能低下を治療するためのプリドピジンの使用 |
| JP2021078504A Pending JP2021119186A (ja) | 2016-08-24 | 2021-05-06 | 機能低下を治療するためのプリドピジンの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021078504A Pending JP2021119186A (ja) | 2016-08-24 | 2021-05-06 | 機能低下を治療するためのプリドピジンの使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11207310B2 (https=) |
| EP (2) | EP3504187B8 (https=) |
| JP (2) | JP6912574B2 (https=) |
| CN (2) | CN109923102B (https=) |
| AU (2) | AU2017315783C1 (https=) |
| BR (1) | BR112019003732A2 (https=) |
| CA (2) | CA3151507C (https=) |
| CL (2) | CL2019000485A1 (https=) |
| DK (1) | DK3504187T3 (https=) |
| ES (1) | ES3025836T3 (https=) |
| FI (1) | FI3504187T3 (https=) |
| HU (1) | HUE071008T2 (https=) |
| IL (1) | IL311081A (https=) |
| MX (2) | MX390627B (https=) |
| PL (1) | PL3504187T3 (https=) |
| PT (1) | PT3504187T (https=) |
| WO (1) | WO2018039477A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG188298A1 (en) | 2010-09-03 | 2013-04-30 | Ivax Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| PE20160195A1 (es) | 2013-06-21 | 2016-05-14 | Teva Pharmaceuticals Int Gmbh | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| TW201613859A (en) * | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| EP4282479A3 (en) | 2015-02-25 | 2024-02-21 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat depression or anxiety |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| ES3025836T3 (en) | 2016-08-24 | 2025-06-09 | Prilenia Neurotherapeutics Ltd | Use of pridopidine for treating functional decline |
| WO2018039475A1 (en) | 2016-08-24 | 2018-03-01 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for treating dystonias |
| NZ750416A (en) | 2016-09-15 | 2022-04-29 | Boehringer Ingelheim Int | Heteroaryl carboxamide compounds as inhibitors of ripk2 |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| AU2018329628B2 (en) | 2017-09-08 | 2021-04-22 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| EP3917380B1 (en) * | 2019-01-31 | 2025-03-19 | F. Hoffmann-La Roche AG | Assessing progression of huntington's disease |
| EP3920924A4 (en) | 2019-02-04 | 2022-11-16 | Prilenia Neurotherapeutics Ltd. | LOW-DOSE PRIDOIDIN FOR THE TREATMENT OF PARKINSON'S DISEASE AND OTHER PARKINSONIC-RELATED DISEASES |
| JP7436524B2 (ja) * | 2019-06-12 | 2024-02-21 | プリレニア ニューロセラピューティクス リミテッド | ハンチントン病及びその症状を治療するためのプリドピジン及びその類似体を含む組成物 |
| CN115551505B (zh) * | 2020-05-04 | 2026-03-17 | 普瑞尼亚神经治疗有限公司 | 使用选择性s1r激动剂治疗病毒性感染、疾病或病症 |
| WO2022219637A1 (en) * | 2021-04-14 | 2022-10-20 | Prilenia Neurotherapeutics Ltd. | Treatment of prodromal huntington disease |
| WO2025164698A1 (ja) * | 2024-01-31 | 2025-08-07 | 株式会社ケイファーマ | ハンチントン病治療剤及び治療用組成物 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9702716D0 (sv) | 1997-07-15 | 1997-07-15 | Ross Nicholas Waters | Substituted phenylazacycloalkanes in the treatment of cognitive disorders |
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| WO2005053703A1 (en) * | 2003-12-02 | 2005-06-16 | Leslie James Sheldon | Combination therapy for dementia, depression and apathy |
| GT200500063A (es) | 2004-04-01 | 2005-10-14 | Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias | |
| CA2584831C (en) | 2004-10-13 | 2013-09-17 | Neurosearch Sweden Ab | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine |
| DOP2006000273A (es) | 2005-12-08 | 2007-10-15 | Aventis Pharma Inc | Uso de un antagonista de cb1 para tratar efectos secundarios y sintomas negativos de la esquizofrenia |
| EP1815857A1 (en) | 2006-02-02 | 2007-08-08 | LEK Pharmaceuticals D.D. | A pharmaceutical composition comprising perindopril |
| US20070286902A1 (en) | 2006-06-07 | 2007-12-13 | Abrika Pharmaceuticals | Dosage forms comprising a short acting sedative-hypnotic or salt thereof |
| SI2146961T1 (sl) | 2007-04-12 | 2014-08-29 | IVAX International GmbH | N-oksidni in/ali di-N-oksidni derivati stabilizatorjev/modulatorjev dopaminskega receptorja, ki izkazujejo izboljšane profile kardiovaskularnih stranskih učinkov |
| US8669048B2 (en) * | 2008-06-24 | 2014-03-11 | Parkinson's Institute | Pluripotent cell lines and methods of use thereof |
| US8384755B2 (en) | 2009-08-26 | 2013-02-26 | Intouch Technologies, Inc. | Portable remote presence robot |
| DK2480218T3 (da) | 2009-09-24 | 2020-08-24 | Capsugel Belgium Nv | Syreresistente kapsler |
| US20110206782A1 (en) | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of dopamine receptor |
| WO2011107583A1 (en) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| CN103080343A (zh) | 2010-07-02 | 2013-05-01 | Skf公司 | 机械部件和用于表面硬化的方法 |
| SG188298A1 (en) | 2010-09-03 | 2013-04-30 | Ivax Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| US8703763B2 (en) | 2011-03-02 | 2014-04-22 | Hoffmann-La Roche Inc. | Bridged piperidine derivatives |
| WO2012159079A1 (en) | 2011-05-18 | 2012-11-22 | The Parkinson's Institute | Assay to determine lrrk2 activity in parkinson's disease |
| CN103958469B (zh) | 2011-09-07 | 2016-04-20 | 梯瓦制药国际有限责任公司 | 一种新的普利多匹定盐酸盐多晶型形态 |
| MX347209B (es) | 2011-12-08 | 2017-04-19 | Teva Pharmaceuticals Int Gmbh | La sal de bromhidrato de pridopidina. |
| US9744155B2 (en) * | 2012-03-28 | 2017-08-29 | Ixcela, Inc. | IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk |
| HK1206297A1 (en) | 2012-04-04 | 2016-01-08 | Teva Pharmaceuticals International Gmbh | Pharmaceutical compositions for combination therapy |
| EP2900226A4 (en) | 2012-09-27 | 2016-03-30 | Teva Pharma | COMBINATION OF RASAGILIN AND PRIDOPIDIN FOR TREATING NEURODEGENERATIVE DISORDERS, ESPECIALLY HUNTINGTON'S DISEASE |
| HK1211525A1 (en) | 2012-09-27 | 2016-05-27 | Teva Pharmaceutical Industries Ltd. | Laquinimod and pridopidine for treating neurodegenerative disorders |
| PE20160195A1 (es) * | 2013-06-21 | 2016-05-14 | Teva Pharmaceuticals Int Gmbh | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| PE20161220A1 (es) | 2014-01-22 | 2016-11-23 | Teva Pharmaceuticals Int Gmbh | Formulaciones de pridopidina de liberacion modificada |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| EP3236964A4 (en) | 2014-12-22 | 2018-09-19 | Teva Pharmaceuticals International GmbH | L-tartrate salt of pridopidine |
| EP4282479A3 (en) * | 2015-02-25 | 2024-02-21 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat depression or anxiety |
| WO2016138135A1 (en) | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Sigma-1 receptor modulators for treating huntington's disease |
| CA2993183A1 (en) | 2015-07-22 | 2017-01-26 | Teva Pharmaceuticals International Gmbh | Pridopidine base formulations and their use |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| WO2017048457A1 (en) | 2015-09-18 | 2017-03-23 | Teva Pharmaceuticals Industries Ltd. | Combination of laquinimod and pridopidine to treat multiple sclerosis |
| US11738012B2 (en) | 2016-02-24 | 2023-08-29 | Prilenia Neurotherapeutics Ltd. | Treatment of neurodegenerative eye disease using pridopidine |
| WO2018039475A1 (en) | 2016-08-24 | 2018-03-01 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for treating dystonias |
| ES3025836T3 (en) | 2016-08-24 | 2025-06-09 | Prilenia Neurotherapeutics Ltd | Use of pridopidine for treating functional decline |
| AU2017326436A1 (en) | 2016-09-15 | 2019-04-11 | Prilenia Neurotherapeutics Ltd | Use of pridopidine for the treatment of anxiety and depression |
| WO2018053275A1 (en) | 2016-09-16 | 2018-03-22 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for the treatment of familial dysautonomia |
| ES2909557T3 (es) | 2016-09-16 | 2022-05-09 | Prilenia Neurotherapeutics Ltd | Utilización de la pridopidina para el tratamiento del síndrome de Rett |
| CA3050700C (en) | 2017-01-20 | 2023-10-03 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for the treatment of fragile x syndrome |
| HRP20251431T1 (hr) | 2017-08-14 | 2026-01-02 | Prilenia Neurotherapeutics Ltd. | Liječenje amiotrofične lateralne skleroze pridopidinom |
| EP3675830A1 (en) | 2017-08-30 | 2020-07-08 | Prilenia Neurotherapeutics Ltd. | High concentration dosage forms of pridopidine |
-
2017
- 2017-08-24 ES ES17844433T patent/ES3025836T3/es active Active
- 2017-08-24 EP EP17844433.7A patent/EP3504187B8/en active Active
- 2017-08-24 AU AU2017315783A patent/AU2017315783C1/en active Active
- 2017-08-24 MX MX2019002265A patent/MX390627B/es unknown
- 2017-08-24 WO PCT/US2017/048461 patent/WO2018039477A1/en not_active Ceased
- 2017-08-24 CN CN201780066778.4A patent/CN109923102B/zh active Active
- 2017-08-24 CA CA3151507A patent/CA3151507C/en active Active
- 2017-08-24 IL IL311081A patent/IL311081A/en unknown
- 2017-08-24 JP JP2019531547A patent/JP6912574B2/ja active Active
- 2017-08-24 HU HUE17844433A patent/HUE071008T2/hu unknown
- 2017-08-24 BR BR112019003732-2A patent/BR112019003732A2/pt not_active Application Discontinuation
- 2017-08-24 CA CA3035092A patent/CA3035092C/en active Active
- 2017-08-24 PT PT178444337T patent/PT3504187T/pt unknown
- 2017-08-24 PL PL17844433.7T patent/PL3504187T3/pl unknown
- 2017-08-24 EP EP25152698.4A patent/EP4516356A3/en active Pending
- 2017-08-24 FI FIEP17844433.7T patent/FI3504187T3/fi active
- 2017-08-24 DK DK17844433.7T patent/DK3504187T3/da active
- 2017-08-24 US US15/685,993 patent/US11207310B2/en active Active
- 2017-08-24 CN CN202211419342.8A patent/CN115671103A/zh active Pending
-
2019
- 2019-02-22 CL CL2019000485A patent/CL2019000485A1/es unknown
- 2019-02-25 MX MX2022003072A patent/MX2022003072A/es unknown
- 2019-12-31 CL CL2019003924A patent/CL2019003924A1/es unknown
-
2020
- 2020-08-27 AU AU2020223736A patent/AU2020223736B2/en active Active
-
2021
- 2021-05-06 JP JP2021078504A patent/JP2021119186A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019524898A5 (https=) | ||
| Kaasenbrood et al. | Opportunistic screening versus usual care for diagnosing atrial fibrillation in general practice: a cluster randomised controlled trial | |
| CN109923102B (zh) | 普利多匹定用于治疗功能下降的用途 | |
| Avivi-Arber et al. | Widespread volumetric brain changes following tooth loss in female mice | |
| Yarnall et al. | Parkinson's disease | |
| US20110130466A1 (en) | Use of rasagiline for the treatment of progressive supranuclear palsy | |
| JP2018506569A (ja) | 認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用 | |
| JP2019524897A (ja) | ジストニアを治療するためのプリドピジンの使用 | |
| JP2019524897A5 (https=) | ||
| JP2019529411A (ja) | 不安症およびうつ病の治療のためのプリドピジンの使用 | |
| Weydt et al. | Clinical trials in spinal and bulbar muscular atrophy—past, present, and future | |
| JP2013032308A (ja) | うつ病治療用または予防用医薬組成物 | |
| CN120284934A (zh) | 一种组合物在制备药物中的应用 | |
| KR20240161650A (ko) | 조현병 환자에서 재발을 예방하는 데 있어서 롤루페리돈의 용도 | |
| ZHANG et al. | Efficacy of acupuncture in combination with medicine for mild cognitive impairment after cerebral infarction: a randomized controlled trial | |
| Fujihara et al. | The impact of lesion location on medication self-management ability in patients with cerebrovascular disease | |
| US20260091028A1 (en) | Method of treating amyotrophic lateral sclerosis with pridopidine | |
| JP2009007278A (ja) | 線維筋痛症の治療薬 | |
| Guido | IL PERCORSO DELLE CURE PALLAITIVE DOMICILIARI NEL PAZIENTE AFFETTO DA MALATTIE NEURODEGENERATIVE DEL MOTONEURONE | |
| Malaspina et al. | Disorders of the Motor Cells: The Motor Neuron Diseases | |
| Ng et al. | Motor neuron disease: causes, classification and treatments | |
| Chandradevan et al. | Acute Post-stroke Hemiparkinsonism and Hemiparesis: A Unique Case with Successful Therapy | |
| Badyal et al. | Safety and efficacy of duloxetine versus venlafaxine in major depression in Indian patients | |
| Waterman | Extending the effects of pulmonary rehabilitation in a community setting | |
| Hernández-Hernández et al. | 481 Hemodynamic evaluation and selection of hypertension treatment |